Atlas Trials

A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

Clinical trial NCT04458857 · COMPLETED

Trial details

NCT number
NCT04458857
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Migraine
Start date
2020-07-15
Primary completion
2024-03-13
Enrollment
235

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.